Digging "10 times growth potential", 2022 Medical Venture Capital New Wind Online Forum is successfully concluded

The topic of the forum from the current popular medical digitalization, to the innovative drugs, genetic therapy, and the diagnosis of molecular diagnosis of medical equipment CROs and the post -new crown era. People listen online and interact enthusiastically.

Since 2021, investment and financing in the field of medical and health can be described as ups and downs: Many companies in the secondary market have experienced a market value "roller coaster", and the rhythm of investment and financing in the first -level market has also slowed down. Essence The trillion medical track is returning to clinical value and innovation.

Driven by the aging population and the upgrading of medical needs, many opportunities in the big health industry still surge, so that entrepreneurs and investment institutions are willing to go all out. According to the data of Tianyan, in the first half of 2022, the number of medical and health equity financing events reached 768, ranking the top three in the industry, second only to advanced manufacturing and corporate services.

With the accumulation of innovative drug research and development experience, innovative drug projects with differentiated and Best-in-Class potential in China have continued to emerge, and the layout of popular targets has entered a harvest period. Many companies have taken a road of going out to sea. In addition, domestic replacement trends are in full swing, especially in the field of medical device. Related policies have been supporting domestic alternatives of medical devices, and more and more high -quality domestic devices are moving towards the market.

A new era of medical innovation has arrived, which requires the continuous attention and unremitting efforts of many roles such as entrepreneurs, investment institutions, and policy makers. For medical companies that "sit for ten years of cold bench", capital is not only an ammunition, defensive weapon, but also a barrier of competition.

In the future, what opportunities and challenges are capital and medical companies facing capital and medical companies? Where will the development of the medical industry go?

On July 20, 36 氪 invited front -line investment institutions and well -known startups in the medical industry to host a 10 -fold growth potential medical venture capital new wind direction online forum, which was divided into one speech+five peak conversations.

From the current popular medical digitalization, to the innovative drugs and genetic treatment of ophthalmology, to the diagnosis of the Molecular diagnosis of medical device CRO and the post -new crown era, five dialogues around the "medical hard technology" and "investment strategy" have attracted super 30,000 people listen online and interact enthusiastically. The following is the guest of this event. Scan the QR code of the picture.

Due to the limited online forum time, only the topics of medical digitalization, ophthalmology innovation drugs, gene therapy, medical device CRO, and molecular diagnosis are covered. It is worthy of analysis.

Next, 36 氪 will also hold an offline conference -August 23, Beijing Wangjing Hyatt Hotel. At that time, we will invite more investment institutions and well -known enterprises of medical and medicine tracks to grow up. Welcome to click the original link and sign up.

sign up

- END -